Literature DB >> 4918227

Parameters of renal functional capacity in reversible hydroureteronephrosis in dogs. VI. Response to mannitol challenge by the chronically obstructed canine kidney and its clinical implication.

A L Finkle, S J Karg, D R Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 4918227     DOI： 10.1016/s0022-5347(17)61739-7

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  7 in total

1.  Discovery of a first-in-class EZH2 selective degrader.

Authors:  Anqi Ma; Elias Stratikopoulos; Kwang-Su Park; Jieli Wei; Tiphaine C Martin; Xiaobao Yang; Megan Schwarz; Violetta Leshchenko; Alexander Rialdi; Brandon Dale; Alessandro Lagana; Ernesto Guccione; Samir Parekh; Ramon Parsons; Jian Jin
Journal:  Nat Chem Biol       Date:  2019-12-09       Impact factor: 15.040

2.  Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies.

Authors:  Lin Qi; Holly Lindsay; Mari Kogiso; Yuchen Du; Frank K Braun; Huiyuan Zhang; Lei Guo; Sibo Zhao; Sarah G Injac; Patricia A Baxter; Jack Mf Su; Sophie Xiao; Stephen W Erickson; Eric J Earley; Beverly Teicher; Malcolm A Smith; Xiao-Nan Li
Journal:  Lab Invest       Date:  2021-11-20       Impact factor: 5.502

3.  Tubular dimensions and juxtaglomerular granulation index in rat kidneys after unilateral obstruction of the ureter. A study of the morphogenesis of hydronephrosis.

Authors:  G E Schubert; R Staudhammer; K Rolle; U Kneissler
Journal:  Urol Res       Date:  1975-10-29

4.  Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method.

Authors:  Kensuke Misawa; Noriyuki Yamaotsu; Shuichi Hirono
Journal:  J Comput Aided Mol Des       Date:  2021-02-26       Impact factor: 3.686

5.  EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications.

Authors:  Zhenghao Li; Hisanori Takenobu; Amallia Nuggetsiana Setyawati; Nobuhiro Akita; Masayuki Haruta; Shunpei Satoh; Yoshitaka Shinno; Koji Chikaraishi; Kyosuke Mukae; Jesmin Akter; Ryuichi P Sugino; Atsuko Nakazawa; Akira Nakagawara; Hiroyuki Aburatani; Miki Ohira; Takehiko Kamijo
Journal:  Oncogene       Date:  2018-03-06       Impact factor: 9.867

6.  Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection.

Authors:  Valeria Barili; Paola Fisicaro; Barbara Montanini; Greta Acerbi; Anita Filippi; Giovanna Forleo; Chiara Romualdi; Manuela Ferracin; Francesca Guerrieri; Giuseppe Pedrazzi; Carolina Boni; Marzia Rossi; Andrea Vecchi; Amalia Penna; Alessandra Zecca; Cristina Mori; Alessandra Orlandini; Elisa Negri; Marco Pesci; Marco Massari; Gabriele Missale; Massimo Levrero; Simone Ottonello; Carlo Ferrari
Journal:  Nat Commun       Date:  2020-01-30       Impact factor: 14.919

Review 7.  The emerging role of epigenetic therapeutics in immuno-oncology.

Authors:  Michael J Topper; Michelle Vaz; Kristen A Marrone; Julie R Brahmer; Stephen B Baylin
Journal:  Nat Rev Clin Oncol       Date:  2019-09-23       Impact factor: 66.675
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.